The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI

Explore the safety and efficacy of different doses of bicyclol in treatment of acute drug-induced liver injury using polyene phosphatidylcholine capsule as the positive control drug.

The study adopted the design of multi center, randomized, double-blind, dose finding, positive control drug, superiority test, using two simulation skills. The qualified subjects, according to the ratio of 1:1:1, were randomized into low dose group and high dose group and positive drug control group, and received a treatment course of 4-8 weeks, all individuals were followed up for 4 weeks after drug withdrawal.

Inclusion criteria

• 18-75 years old, male or female;
• Meet the standard of clinical diagnosis of acute drug-induced liver injury, the RUCAM causality scale score is more than or equal to 6 points. If the RUCAM causality scale score is 3-5,the subject needs three liver disease experts to confirm whether he is DILI patient, at least two of three liver disease experts should have the same judgment;
• The serum ALT is between 3and 20 times ULN, but TBiL is less than or equal to 2 times ULN;
• Liver biochemical indexes(ALT,AST,ALP,GGT,TBiL,albumin,prothrombin time) abnormalities lasted less than 90 days;
• Patients can understand the nature of the experiment, the nature of the disease, the characteristic of drugs, related treatment methods and the risk they may need to bear if they participate in the test, and sign the informed consent.

Exclusion criteria

• Occurrent liver injury caused by other reasons, such as viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease etc;
• Acute liver failure or liver function decompensation patient perform, such as hepatic encephalopathy, ascites, albumin is less than or equal to 35g / L, The international standardized ratio (INR) of thrombin is more than 1.5;
• Serum creatinine is more than 1.5 times ULN;
• Severe or life-threatening heart, lung, brain, kidney, gastrointestinal and systemic diseases;
• Taking drugs that may affect observation of curative effect of the experimental drug during the study;
• Allergy or intolerance to experimental drugs;
• With no ability to express their complaints, such as mental illness and severe neurosis patient;
• The patient can not cooperate and poor compliance;
• Pregnant and lactating women or women preparing for pregnancy;
• The patient participated in other clinical trials in 3 months before entering this study;
• Using other liver-protective drugs except ursodeoxycholic acid or ademetionine within three days;
• The researchers believe not suitable.